Penny-Stock Nutraceutical Firm Buys Preclinical Psilocybin Biotech With Stock, No Cash
BDPT has more than doubled off its 52-week low of $0.001.
Summary
BioAdaptives signed a definitive agreement dated October 29, 2026 to acquire Xycota Biosciences, a preclinical CNS company, paying no cash — consideration is preferred stock. This is the public rollout of the deal disclosed in the 8-K filed November 4. At closing BioAdaptives issues Economic Preferred representing 40% of total voting power and economic ownership, while Voting Preferred carrying 51% of voting power is initially issuable to CEO James E. Keener and shifts to Xycota members on milestones, a nutraceutical spin-off, or another transfer event. Xycota's lead asset XYCO-02 is low-dose oral psilocybin aimed at sub-perceptual dosing for mild PTSD; the supporting data is a 2026 rat study in Fragile X, not human PTSD work, and no Xycota product has been in a company-sponsored human trial or approved by any regulator. Funding is thin and conditional: $150,000 in four tranches after closing, up to $800,000 of additional investment rights over 36 months, and up to $160,000 for reporting and spin-off costs, all through 12-month convertible notes with a 10% original issue discount and 10% one-time interest charge. The agreement terminates automatically if closing has not occurred by June 30, 2027, and the company's Q2 2026 10-Q already flagged going-concern doubt and heavy dilution from debt conversions — preferred and note conversion will dilute existing holders further.
At the time of this announcement, BDPT was trading at $0.00 on OTC in the Life Sciences sector, with a market capitalization of approximately $315.1K. The 52-week trading range was $0.00 to $0.08. This news item was assessed with positive market sentiment and an importance score of 7 out of 10. Source: ACCESS Newswire.